Citations

Clear

6273 citation(s) found for "To, Andrew".

Statistical modeling of CALGB 80405 (Alliance) to identify influential factors in metastatic colorectal cancer (CRC) dependent on primary (1o) tumor side.
Hayete, Boris , Khalil, Iya, Wuest, Diane, Rich, Kelly , Niedzwiecki, Donna , Lenz, Heinz‐Josef , Innocenti, Federico , Niedzwiecki, Donna , Furchtgott, Leon , Swanson, David Michael , Rich, Kelly, Nixon, Andrew B. , Meyerhardt, Jeffrey A. , O’Reilly, Eileen M. , Ou, Fang‐Shu , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3528-3528

10.1200/jco.2017.35.15_suppl.3528 Get It

3528 Background: CALGB 80405 is a phase III clinical trial of FOLFOX and FOLFIRI w/ randomly assigned cetuximab or bevacizumab. Novel machine learning approaches to the study dataset provide valuable insights into CRC prognosis and management of CRC progression. Methods: Using a Monte Carlo Bayesian Generalized Linear Model analytical platform, we built an ensemble of models for overall survival (OS). We used 99 baseline and demographic variables, including 1904 patients w/ 1o side and 949 w/ KRAS wild-type status. Building an ensemble of predictive models reduces risk of overfitting, estimates model uncertainty and identifies key variables by model consensus as measured by ensemble frequency (freq). We fit gender and 1o side (L vs R) stratum-specific models to examine differences in drivers of disease in those strata. Results: 1o side (avg Cox hazard ratio = 0.89, R side reference), ECOG performance status (1.30, reference level 0), AST concentration (1.01), peripheral neutrophil percentage (1.01) and local primary and abdominal site of disease indicators (1.22; 1.26) were key variables predictive of OS ( > 75% freq). In 1o side stratum-specific models, urine protein level (1.61), treatment intent (0.75, nonpalliative as reference) and hemoglobin concentration (0.85) were more associated w/ L side progression (freq > 85% in L stratum model, < 20% in R), while liver and lung sites of disease (2.3; 1.09) were more associated w/ R side progression (freq > 65% in R stratum model, < 20% in L). Predictors of 1o left-sidedness included age (avg log odds ratio = 0.02), hemoglobin (0.41), and abdominal (3.79) and liver (0.68) sites of disease. Modest differences in disease prognostic factors existed between genders: women more influenced by metastatic status, age, liver site of disease and creatinine level; men more influenced by urine protein level and prior diabetes. Conclusions: 1o side plays a central role in potentially explaining both variation in OS and differences in drivers of OS. Availability of these measures at baseline enables better sense of disease course at initiation of treatment. Support: U10CA180821, U10CA180882, Eli Lilly & Co., Genentech, Pfizer Clinical trial information: NCT00265850.
Non-invasive clinical visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: A pilot study.
Nevala, Wendy K. , Paulsen, Andrew, Hung, Joseph C., Gansen, Denise N. , Wiseman, Gregory A., Signore, Alberto , Markovic, Svetomir N. , Galli, Filippo , Suman, Vera J. , Erickson, Lori A. , Marchetti, Paolo

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 3034-3034

10.1200/jco.2017.35.15_suppl.3034 Get It

3034 Background: Unique to modern immune therapy for cancer is that early in the course of treatment, patients frequently exhibit transient tumor enlargement (pseudo-progression, pPROG) due to tumor infiltration by lymphocytes (TIL). Currently, pPROG cannot be reliably distinguished from true tumor progression (PROG). There is a need for biomarker techniques to discriminate pPROG (effect of therapy) and PROG (therapy failure). Nuclear medicine offers radiopharmaceuticals capable of imaging immune cells; images can be fused to evaluate functional and anatomic characteristics of tumors, and potentially discriminate pPROG from PROG. Methods: In our study of metastatic melanoma patients, SPECT/CT imaging with 99mTc-interleukin-2 (99mTc-IL2) was performed to visualize TIL. Images were collected before/after 12 weeks of ipilimumab (IPI) or pembrolizomab (PEMBRO) therapy. The 99mTc-IL2 tracer was synthesized by conjugating succinimidyl-6-hydrazinopyridine-3-carboxylate (HYNIC-NHS) with commercial interleukin-2 (Aldesleukin). HYNIC-IL2 was incubated with tricine, 99mTcO4- (370-740 MBq) and SnCl2. After labelling 99mTc-IL2 was purified by reverse-phase chromatography and diluted in 5% glucose with 0.1% human albumin before injection. Five patients were enrolled in this study. Two patients failed to complete the 12 week 99mTc-IL2 scan due to discontinuation of IPI after: 1) grade 3 colitis and 2) patient refusal for adverse events attributed to IPI. No adverse events attributable to the tracer infusion were reported. Results: Metastatic lesions could be visualized by the tracer. Some lesions decreased in size, while others increased. A positive correlation was found between size and 99mTc-IL2 uptake, before and after therapy, suggesting the potential discrimination of tumor PROG (no 99mTc-IL2 uptake) from pPROG (high 99mTc-IL2 uptake). Immunohistochemical staining for TIL of 99mTc-IL2 positive and negative lesions are illustrated. Conclusions: The results demonstrate feasibility of 99mTc-IL2 imaging as a clinically useful tool capable of discriminating tumor PROG from pPROG. A clinical validation study is in progress. Clinical trial information: NCT01789827.
Individualized screening trial of innovative glioblastoma therapy (INSIGhT).
Trippa, Lorenzo , Gaffey, Sarah, Lee, Eudocia Q. , Ahluwalia, Manmeet S. , Colman, Howard , Groot, John Frederick De, Lassman, Andrew B. , Reardon, David A. , Schiff, David , Welch, Mary , Wen, Patrick Y. , Ahluwalia, Manmeet S , Alexander, Brian M. , Arrillaga, Isabel, Tanguturi, Shyam K , Colman, Howard , Galanis, Evanthia , Drappatz, Jan , Nabors, Burt , Ligon, Keith L , Wen, Patrick Yung

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS2079-TPS2079

10.1200/jco.2017.35.15_suppl.tps2079 Get It

TPS2079 Background: Patient with glioblastoma (GBM) with unmethylated MGMT promoters derive limited benefit from temozolomide (TMZ) and have dismal outcome. Prioritizing the numerous available therapies and biomarkers for late stage testing requires an efficient clinical testing platform. INSIGhT (NCT02977780) is a biomarker-based, Bayesian adaptively randomized, multi-arm phase II platform screening trial for patients with newly diagnosed GBM and unmethylated MGMT promoters. Methods: INSIGhT compares experimental arms to a common control of standard concurrent TMZ and radiation therapy (RT) followed by adjuvant TMZ. The primary endpoint is overall survival (OS). Patients with newly diagnosed, unmethylated GBM that are IDH R132H mutation negative, and with genomic data available or who consent to whole exome sequencing through the ALLELE companion study for biomarker grouping are eligible. Two experimental arms consist of concurrent RT/TMZ followed by adjuvant neratinib (EGFR, HER2, and HER4 inhibitor) or abemaciclib CDK 4/6 inhibitor), respectively, in place of TMZ. The other experimental arm is CC-115 (TORC1/2 and DNA PK inhibitor), which replaces TMZ in both the concurrent and adjuvant phases. Biomarker groups include: EGFR + patients with EGFR amplification/mutation; PI3K + patients with PIK3CA mutation/amplification, PIK3R1 mutation, AKT3amplification, PIK3C2B > 1 copy gain, or PTEN dual loss; CDK: + patients with wild-type RB1 and CDK4 amplification, CDK6 amplification, or CDKN2A > 1 copy loss. Given the lack of pretrial biomarker data and the anticipated overlap of the groups, randomization will initially be equal. As the trial progresses, randomization probabilities will be adapted based on the Bayesian estimation of the probability of treatment impact on progression-free survival (PFS). These randomization probabilities can vary among the biomarker groups so predictive biomarkers will be identified and utilized if present. Treatment arms may drop due to low probability of treatment impact on OS, and new arms may be added. Experimental arms are compared only with control and should be thought of as discrete experimental questions, with INSIGhT being open to new investigators with proposed therapeutic hypotheses. Clinical trial information: NCT02977780.
Establishment of an in vivo turkey model for the study of flexor tendon repair
Kadar, Assaf , Liu, Haoyu , Vrieze, Alyssa, Meier, Thomas R., Thoreson, Andrew R. , Amadio, Peter C. , Moran, Steven L. , Zhao, Chunfeng , Vrieze, Alyssa M

Mayo Clinic

Journal of Orthopaedic Research | September 6, 2018 | Volume: 36 | Issue: 9 | Pages: 2497-2505

10.1002/jor.23904 | PMID 29603350 Get It

ABSTRACTFlexor tendon injuries are common and pose a clinical challenge for functional restoration. The purpose of our study was to assess the adequacy of the turkey as a large animal model for flexor tendon injuries in vivo. Twenty‐four male turkeys underwent surgical flexor tendon cut and repair. Turkeys were allocated to five groups postoperatively: (1) foot casted in extension and sacrificed after 3 weeks; (2) foot casted in extension and sacrificed after 6 weeks; (3) foot casted in flexion and sacrificed after 3 weeks; (4) foot casted in flexion and sacrificed after 6 weeks; and (5) foot casted in flexion for 6 weeks and then free roaming allowed for an additional 3 weeks before sacrifice. After sacrifice, digits were collected and analyzed for adhesion formation, healing at the macrolevel and histologically, and biomechanical properties—including friction, work of flexion, stiffness, and strength of repair. All turkeys survived anesthesia and surgery. Tendon rupture occurred in all extension casts and in 11% of those casted in flexion. Friction and work of flexion were significantly higher in the repaired digit than the control digit. There was a correlation between duration of immobilization and repair strength. Histologically, the tendon healed with tenocytes migrating into the gap and producing collagen fibers. We have, for the first time, studied flexor tendon injury and repair using turkeys in terms of anesthesia, surgical procedures, postoperative care, and animal husbandry. The findings regarding functional and histological results from this novel avian model were comparable to the most commonly used mammal model. © 2018 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:2497–2505, 2018.
SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).
Widemann, Brigitte C. , Meyer, Christian F. , Tine, Brian Andrew Van, Turpin, Brian , Jayaprakash, Nalini, Okuno, Scott H. , Helman, Lee J. , Onwudiwe, Ndidi, Steinberg, Seth M. , Coté, Gregory M. , Chugh, Rashmi , Milhem, Mohammed , Kim, AeRang , Dombi, Eva , Reinke, Denise K. , Cichowski, Karen , Perentesis, John P.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 11053-11053

10.1200/jco.2016.34.15_suppl.11053 Get It

Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).
Evens, Andrew M. , Gascoyne, Randy D. , Quon, Andrew , Ansell, Stephen M. , Petrich, Adam M., Chang, Julie , O’Brien, Timothy E., Cheema, P. , Cescon, Terrence P., Sturtz, Keren , Evens, Andrew M , Hong, Fangxin , Habermann, Thomas M. , Advani, Ranjana H. , Witzig, Thomas E. , Wagner, Lynne I. , Kahl, Brad S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7507-7507

10.1200/jco.2016.34.15_suppl.7507 Get It

Outcomes in patients with myelofibrosis and RBC-transfusion dependence in the phase III PERSIST-1 study of pacritinib vs. best available therapy.
Harrison, Claire , Egyed, Miklós , Szőke, Anita , Suvorov, Aleksandr , Perkins, Andrew C. , Mayer, Jiřı́ , Schouten, Harry C. , Tosi, Patrizia , Zhou, Huafeng, Nangalia, Jyoti , Ganly, Peter S. , Farber, Charles Michael , Zachée, Pierre , Scheid, Christof , Dean, James P. , Kiladjian, Jean‐Jacques , Vannucchi, Alessandro M. , Mead, Adam J. , Mesa, Ruben A. , Perkins, Andrew C

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7066-7066

10.1200/jco.2016.34.15_suppl.7066 Get It

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
Tritchler, David , Starr, Mark D. , Brady, John C. , Hurwitz, Herbert I. , Mannel, Robert S., Tewari, Krishnansu S. , Gray, Heidi J. , Boente, Matthew, Deng, Wei , Burger, Robert A. , Birrer, Michael J. , Secord, Angeles Alvarez , Liu, Yingmiao , Lankes, Heather A. , O’Malley, David M. , Bakkum‐Gamez, Jamie N. , Fujiwara, Keiichi , Deng, Wei, Nixon, Andrew B.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 5521-5521

10.1200/jco.2016.34.15_suppl.5521 Get It

Final results of a phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX.
Ko, Andrew H. , Chiorean, E. Gabriela , Kwak, Eunice L., Lenz, Heinz‐Josef , Nadler, Paul I., Wood, Debra L., Fujimori, Masamoto, Inada, Tetsuhi, Kouji, Hiroyuki , Fujimori, Masamoto, McWilliams, Robert R.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: e15721-e15721

10.1200/jco.2016.34.15_suppl.e15721 Get It

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.
Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Vonderheide, Robert H. , Wolff, Robert A. , Giordano, Heidi, Goble, Sandra, Shroff, Rachna T. , Domchek, Susan M. , McWilliams, Robert R. , Biankin, Andrew V. , Alberts, Steven R. , Lin, Kevin

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4110-4110

10.1200/jco.2016.34.15_suppl.4110 Get It